J. Raniwalla

544 total citations
19 papers, 427 citations indexed

About

J. Raniwalla is a scholar working on Psychiatry and Mental health, Pharmacology and Endocrinology, Diabetes and Metabolism. According to data from OpenAlex, J. Raniwalla has authored 19 papers receiving a total of 427 indexed citations (citations by other indexed papers that have themselves been cited), including 13 papers in Psychiatry and Mental health, 7 papers in Pharmacology and 3 papers in Endocrinology, Diabetes and Metabolism. Recurrent topics in J. Raniwalla's work include Schizophrenia research and treatment (11 papers), Treatment of Major Depression (6 papers) and Electroconvulsive Therapy Studies (6 papers). J. Raniwalla is often cited by papers focused on Schizophrenia research and treatment (11 papers), Treatment of Major Depression (6 papers) and Electroconvulsive Therapy Studies (6 papers). J. Raniwalla collaborates with scholars based in United Kingdom, United States and Ireland. J. Raniwalla's co-authors include AM Jones, Robin Emsley, Peter J. Bailey, J.A. Tweed, Stephen Cooper, Sonia Dollfus, M. Petit, Francine L. Kelly, E. Leutenegger and Ihor W Rak and has published in prestigious journals such as Biological Psychiatry, Psychopharmacology and Schizophrenia Research.

In The Last Decade

J. Raniwalla

17 papers receiving 400 citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
J. Raniwalla United Kingdom 8 393 109 84 62 38 19 427
Maxim V. Cheine Finland 7 384 1.0× 64 0.6× 134 1.6× 97 1.6× 38 1.0× 8 447
C.G.G. Link United Kingdom 8 500 1.3× 143 1.3× 80 1.0× 79 1.3× 75 2.0× 14 585
Michel Patris France 7 355 0.9× 190 1.7× 85 1.0× 63 1.0× 40 1.1× 15 425
Jaromír Švestka Czechia 11 290 0.7× 107 1.0× 52 0.6× 106 1.7× 40 1.1× 73 414
W. Chrzanowski Poland 7 413 1.1× 126 1.2× 110 1.3× 96 1.5× 26 0.7× 11 497
R.N. Marcus United States 5 396 1.0× 71 0.7× 48 0.6× 59 1.0× 38 1.0× 10 449
Marc Eneman Belgium 5 235 0.6× 51 0.5× 77 0.9× 73 1.2× 37 1.0× 12 313
C. A. Gagiano South Africa 6 245 0.6× 144 1.3× 42 0.5× 49 0.8× 57 1.5× 18 384
Colette Kosik‐Gonzalez United States 10 375 1.0× 167 1.5× 47 0.6× 72 1.2× 23 0.6× 18 558
Shubhra Mace United Kingdom 9 277 0.7× 125 1.1× 55 0.7× 93 1.5× 59 1.6× 14 467

Countries citing papers authored by J. Raniwalla

Since Specialization
Citations

This map shows the geographic impact of J. Raniwalla's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by J. Raniwalla with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites J. Raniwalla more than expected).

Fields of papers citing papers by J. Raniwalla

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by J. Raniwalla. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by J. Raniwalla. The network helps show where J. Raniwalla may publish in the future.

Co-authorship network of co-authors of J. Raniwalla

This figure shows the co-authorship network connecting the top 25 collaborators of J. Raniwalla. A scholar is included among the top collaborators of J. Raniwalla based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with J. Raniwalla. J. Raniwalla is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

19 of 19 papers shown
1.
Emsley, Robin, J. Raniwalla, Peter J. Bailey, & AM Jones. (2000). A comparison of the effects of quetiapine (‘Seroquel’) and haloperidol in schizophrenic patients with a history of and a demonstrated, partial response to conventional antipsychotic treatment. International Clinical Psychopharmacology. 15(3). 121–131. 147 indexed citations
2.
Cooper, Stephen, et al.. (2000). Zotepine in the prevention of recurrence: a randomised, double-blind, placebo-controlled study for chronic schizophrenia. Psychopharmacology. 150(3). 237–243. 45 indexed citations
3.
Raniwalla, J., et al.. (2000). Quetiapine. Drug Safety. 23(4). 295–307. 62 indexed citations
4.
Tweed, J.A., et al.. (2000). The safety and efficacy of zotepine in the treatment of schizophrenia: Results of a one-year naturalistic clinical trial. International Journal of Psychiatry in Clinical Practice. 4(4). 299–306. 8 indexed citations
5.
Emsley, Richard, et al.. (2000). Efficacy of seroquel in treating all of the positive and negative symptoms of schizophrenia. Schizophrenia Research. 41(1). 203–203. 3 indexed citations
6.
Rak, Ihor W & J. Raniwalla. (2000). Maintenance of long-term efficacy with ‘seroquel’. Schizophrenia Research. 41(1). 205–205. 5 indexed citations
7.
Cooper, Stephen, et al.. (2000). A placebo‐controlled comparison of zotepine versus chlorpromazine in patients with acute exacerbation of schizophrenia. Acta Psychiatrica Scandinavica. 101(3). 218–225. 48 indexed citations
8.
Rak, Ihor W, et al.. (2000). Weight changes in patients treated with seroquel (quetiapine). Schizophrenia Research. 41(1). 206–206. 16 indexed citations
9.
Emsley, Richard, J. Raniwalla, Paul Bailey, & AM Jones. (1999). Efficacy and tolerability of ‘Seroquel’ compared with haloperidol in schizophrenic patients partially responsive to conventional antipsychotic treatment. European Neuropsychopharmacology. 9. 267–267. 5 indexed citations
10.
Raniwalla, J., et al.. (1997). A DOUBLE‐BLIND, COMPARATIVE STUDY OF DOTHIEPIN AND CLOMIPRAMINE IN THE TREATMENT OF MAJOR DEPRESSIVE ILLNESS. International Journal of Clinical Practice. 51(6). 360–363. 1 indexed citations
11.
Cooper, S.J., et al.. (1997). Zotepine in the prevention of relapse. Biological Psychiatry. 42(1). 41S–41S. 6 indexed citations
12.
Hellewell, Jonathan S.E., et al.. (1997). P.2.101 ‘Seroquel’ (quetiapine) in the treatment of schizophrenia — overview of efficacy data in 6 phase II/III clinical trials. European Neuropsychopharmacology. 7. S224–S224. 1 indexed citations
13.
Hellewell, Jonathan S.E., et al.. (1997). P.2.100 Extrapyrimidal symptom and tolerability profile of ‘Seroquel’™ (quetiapine): An overview of phase II/III placebo controlled trials. European Neuropsychopharmacology. 7. S224–S224. 1 indexed citations
14.
Tweed, J.A., et al.. (1997). A Multicentre Naturalistic Long Term Study of Zotepine. European Psychiatry. 12(S2). 214s–214s. 1 indexed citations
15.
Petit, M., J. Raniwalla, J.A. Tweed, et al.. (1996). A comparison of an atypical and typical antipsychotic, zotepine versus haloperidol in patients with acute exacerbation of schizophrenia: a parallel-group double-blind trial.. PubMed. 32(1). 81–7. 60 indexed citations
16.
Cooper, S.J., et al.. (1996). Zotepine in acute exacerbation of schizophrenia: A comparison versus chlorpromazine and placebo. European Neuropsychopharmacology. 6. 148–148. 8 indexed citations
17.
Raniwalla, J., J.A. Tweed, Sonia Dollfus, & M.-A. Petit. (1996). A comparison of an atypical (zotepine) and classical (haloperidol) antipsychotic, in patients with acute exacerbation of schizophrenia. Schizophrenia Research. 18(2-3). 133–133. 2 indexed citations
18.
Petit, M.-A., J. Raniwalla, E. Leutenegger, J.A. Tweed, & Francine L. Kelly. (1995). P-4-20 Double-blind study of zotepine vs haloperidol in schizophrenia. European Neuropsychopharmacology. 5(3). 333–333. 1 indexed citations
19.
Hopkins, John, I. McConnell, & J. Raniwalla. (1981). Antigen-induced non-specific suppressor factor in sheep efferent lymph is prostaglandin E2.. PubMed. 43(1). 205–12. 7 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Maxim V. Cheine Breakdown of academic impact, for papers by C.G.G. Link Breakdown of academic impact, for papers by Michel Patris Breakdown of academic impact, for papers by Jaromír Švestka Breakdown of academic impact, for papers by W. Chrzanowski Breakdown of academic impact, for papers by R.N. Marcus Breakdown of academic impact, for papers by Marc Eneman Breakdown of academic impact, for papers by C. A. Gagiano Breakdown of academic impact, for papers by Colette Kosik‐Gonzalez Breakdown of academic impact, for papers by Shubhra Mace
Rankless by CCL
2026